Intelligence Feed event · Equity · 2026-10-04

    Genmab Reports 45.9% ORR in Phase 2 RAINFOL-01 Ovarian Cancer Trial

    Question

    Genmab Reports 45.9% ORR in Phase 2 RAINFOL-01 Ovarian Cancer Trial

    Direct answer

    Genmab released top-line Phase 2 data from the RAINFOL-01 trial evaluating antibody-drug conjugate rinatabart sesutecan (Rina-S) in patients with platinum-resistant ovarian cancer. The candidate achieved a confirmed 45.9% objective response rate. The trial demonstrated a median duration of response of 12.1 months and median progression-free survival of 9.5 months across treated patient cohorts, showing antitumor activity in difficult-to-treat settings.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-04
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Genmab Reports 45.9% ORR in Phase 2 RAINFOL-01 Ovarian Cancer Trial”, revision 1, evidence through 2026-10-04. https://marketontology.com/market-events/2026-10-04/genmab-reports-45-9-orr-in-phase-2-rainfol-01-ovarian-cancer-trial-f33700

    EQUITY
    Genmab Reports 45.9% ORR in Phase 2 RAINFOL-01 Ovarian Cancer Trial
    Genmab released top-line Phase 2 data from the RAINFOL-01 trial evaluating antibody-drug conjugate rinatabart sesutecan (Rina-S) in patients with platinum-resistant ovarian cancer. The candidate achieved a confirmed 45.9% objective response rate. The trial demonstrated a median duration of response of 12.1 months and median progression-free survival of 9.5 months across treated patient cohorts, showing antitumor activity in difficult-to-treat settings.
    GMAB
    Impact
    64
    OCT 4
    SIG
    88%
    GMAB
    Genmab Reports 45.9% ORR in Phase 2 RAINFOL-01 Ovarian Cancer Trial
    Genmab released top-line Phase 2 data from the RAINFOL-01 trial evaluating antibody-drug conjugate rinatabart sesutecan (Rina-S) in patients with platinum-resistant ovarian cancer. The candidate achieved a confirmed 45.9% objective response rate. The trial demonstrated a median duration of response of 12.1 months and median progression-free survival of 9.5 months across treated patient cohorts, showing antitumor activity in difficult-to-treat settings.
    → Clinical trial validation of Rina-S efficacy metrics increases commercialization value and royalty estimates within GMAB's oncology pipeline.
    Impact
    Genmab released top-line Phase 2 data from the RAINFOL-01 trial evaluating antibody-drug conjugate rinatabart sesutecan (Rina-S) in patients with platinum-resistant ovarian cancer. The candidate achieved a confirmed 45.9% objective response rate. The trial demonstrated a median duration of response of 12.1 months and median progression-free survival of 9.5 months across treated patient cohorts, showing antitumor activity in difficult-to-treat settings.
    Affected
    GMAB
    Transmission
    Clinical trial validation of Rina-S efficacy metrics increases commercialization value and royalty estimates within GMAB's oncology pipeline.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    GMABoncology pipeline clinical asset deriskingUp1-5dReported Phase 2 RAINFOL-01 ORR of 45.9% and median PFS of 9.5 months.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month